Oesophageal cancer: an overview of a deadly disease by White, RE & Parker, RK
The Annals of African Surgery; Vol. 1, November 2007 33
Summary
Oesophageal cancer (OC) is one of the deadliest 
cancers in the world. Although it affects many 
people throughout East Africa, relatively little 
work has been done to fully understand this 
disease. This review addresses recent changes 
in the understanding of OC from a global 
perspective, with special attention given to OC 
in Kenya.
Epidemiology
Oesophageal cancer is the eighth most common 
cancer worldwide, and the sixth most common 
cause of death from cancer. From a worldwide 
perspective, one of the most striking features of 
oesophageal cancer is the extreme geographic 
variation in incidence. At a global level, a 20-fold 
difference is seen in offi cial statistics between 
high-risk and low risk areas (1). This difference 
becomes even more striking when one looks at 
specifi c high-risk areas within certain countries. 
For example, while the incidence annually 
among women in North America is close to 
2 cases per 100,000 population, the incidence 
among women in Iran has historically been 
estimated to be close to 100 times higher, 
and the annual death rate for OC in Linxian, 
People’s Republic of China exceeds 100 deaths 
per 100,000 population (1,2). One therefore 
needs really to consider areas where OC is 
endemic separately from non-endemic areas. 
Those areas in which OC should be considered 
endemic are listed in Table 1. It should be noted 
that even within these “hotspots” of OC, there 
is extreme variation within relatively short 
geographic distances (1-3).
The vast majority of oesophageal cancer 
consists of either oesophageal squamous cell 
carcinoma (OSCC), or adenocarcinoma (AC) (5). 
Other malignancies constituting less than 1% of 
total oesophageal malignancies include small cell 
carcinoma, melanoma, malignant mesenchymal 
tumours (including Kaposi’s Sarcoma), and 
lymphomas. From a global perspective, OSCC 
accounts for approximately 80% of OC, and is 
clearly the predominant type in endemic areas 
(1,2,4,5). OSCC tends to occur more commonly 
among the black population (6), while AC is 
increasing among the white population in non-
endemic areas (7). While OC in general tends to 
be a male dominated disease (male:female ratio 
of 5-7:1), a common fi nding in endemic areas is 
a more evenly distributed incidence between 
genders, with male:female ratios of 1–2:1 (1,4,5). 
In many western countries, AC is increasing 
rapidly, and the incidence has surpassed that of 
OSCC. In the USA, for example, AC overtook 
OSCC as the predominant type in the late 1980’s 
and is now three times more common than 
OSCC, increasing at a rate of 5%-10% per year, 
making it the fastest growing cancer incidence 
rate in the country (7). One must bear in mind 
that the absolute numbers still remain relatively 
small compared to endemic areas. The overall 
incidence of OC continues to rise, with most of 
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the increase due to the rise of AC in non-endemic 
areas (8). Average age at diagnosis of OC tends 
to be in the 50’s and 60’s, with AC presenting in 
patients about 10 years older than in OSCC (9).
However, in some endemic areas, this may vary 
considerably. White et al reported in 2002 that 
in an endemic area of Kenya, 11% of all patients 
with OC were 30 years of age or less (5).
Overall survival from OC remains low and 
varies somewhat between geographic locations, 
with 5 year survival in the USA approximately 
16% ,while in Europe it is 10% (10,11). This 
difference is probably largely due to differences 
in stage at diagnosis.
There does not seem to be signifi cant 
survival differences between endemic and non-
endemic areas when differences in treatment 
options and availability are considered. While 
in China, the survival is essentially equal to 
that of the USA, survival in Africa tends to be 
lower. However, in a case series of surgically 
treated patients in East Africa, overall median 
survival of 24 months was reported (12,13). A 
great deal of debate centers around whether 
or not OSCC and AC have different survival 
patterns. Evidence can be found in the literature 
for increased survival with either OSCC or AC 
(14,15). It is a complex issue, however the truth 
may be more refl ective of differences in regional 
access to health care and variable comorbidities 
than in actual survival differences between 
OSCC and AC.












While there are signifi cant differences between 
AC and OSCC, there appears to be a common 
fi nal pathway of progression from dysplasia 
(mild, moderate and severe), to mucosal cancer 
to invasive carcinoma. While mild dysplasia 
seems to frequently spontaneously regress, 
the fi nding of moderate or severe dysplasia 
appears to be much more predictive of the 
development of frank carcinoma. The primary 
risk factor for the development of AC appears 
to be gastro-oesophageal refl ux disease (GORD) 
with subsequent development of Barrett’s 
oesophagus (BO) and Barrett’s dysplasia. These 
and other risk factors for the development of 
OC are summarized in Table 2.
Clinical Presentation/
Diagnosis
For the majority of patients, OC is discovered 
in one of two ways. The fi rst, and by far the 
most common course throughout the world, is 
for patients to present with symptoms usually 
indicative of advanced lesions. Secondly, 
patients may present with early lesions 
discovered through surveillance programs for 
patients with GORD, or after endoscopy for 
non-specifi c dyspepsia. These two presentations 
will be discussed separately.
Throughout most of the world, most patients 
present to health care personnel only after 
symptoms of OC develop. The nature of OC is 
such that symptoms generally do not develop 
until a signifi cant portion of the oesophageal 
lumen is obstructed. Since intra-lumenal growth 
is a relatively late phenomenon in the course 
of the disease, these patients present with 
advanced disease, often with large primary 
tumours, regional lymph node involvement, 
and distant metastases. The most common 
presenting symptoms are dysphagia and 
weight loss, both of which are late symptoms. 
Dysphagia has been reported to occur only 
after the tumour encroaches on 75%-90% of the 
oesophageal circumference (36). In the author’s 
institution where 200-300 new cases of OC are 
seen annually–nearly all patients present with 
signifi cant dysphagia. Endoscopic dilation is 
required in approximately 95% of cases simply 
to allow passage of the endoscope (personal 
data). Interestingly, most patients can accurately 
describe the level of their obstruction (upper, 
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mid, or lower oesophagus) based upon their 
symptoms. Odynophagia, vomiting, chest pain, 
and hematemesis are less common presenting 
symptoms (4,37). Cough productive of purulent 
sputum, particularly occurring immediately after 
oral intake, is highly suggestive of malignant 
tracheo oesophageal fi stula. Hoarseness of the 
voice is also a particularly ominous symptom, 
as this most often indicates recurrent laryngeal 
nerve involvement, or occasionally direct 
involvement of the larynx. A small percentage 
of relatively earlier lesions will present after 
food bolus obstruction of the oesophagus. After 
clearing of the obstruction (either spontaneously 
or via intervention), follow-up studies may reveal 
the presence of a non-obstructing oesophageal 
lesion which would not have otherwise been 
discovered.
With the rising incidence of AC in western 
countries, and the recognition of the association 
of GORD and Barrett’s oesophagus, a new 
group of patients with early lesions discovered 
through screening or surveillance programs is 
emerging. These patients are generally found 
to have either Barrett’s oesophagus or Barrett’s 
dysplasia, and are then regularly followed with 
surveillance endoscopy. Several techniques 
have evolved for increasing sensitivity in 
fi nding early malignant or pre-malignant 
lesions. Chromoendoscopy involves endoscopic 
evaluation after staining with vital dyes such as 
Lugol’s iodine, crystal violet, indigo carmine, 
and methylene blue. This technique has 
increased sensitivity and specifi city to 89% and 
86% respectively, for evaluation of Barrett’s 
Table 2: Risk factors associated with oesophageal cancer development (16)
Squamous Cell Carcinoma Adenocarcinoma Squamous cell carcinoma and 
adenocarcinoma
History of Head and Neck Cancer*
Alcohol Consumption* (RR = 2.9–7.4)
Caustic injury to the oesophagus*
Achalasia cardia*
Gastro-oesophageal Reflux Disease* (RR 
= 2.5–40) (27,29)
Obesity (21,27-30)
Eradication of H. pylori infection††††
History of breast cancer with radiation 
therapy*
Smoking* (OSCC RR = 10, AC RR = 1.5–4) 
(20,21,27)
Occupational exposure (possibly airborne 
contaminants) (32,33)
Socioeconomic status (possibly 








Effects of NSAIDS  (20,24,27,35)
Exposure/consumption of
    N-nitroso compounds and
        polycyclic aromatic 
        hydrocarbons (20-23)
    Hot beverages
    Betel nut
Dietary Deficiencies
    Vitamins C,E, riboflavin, zinc,
    Selenium (24,26)
    Fresh fruits and vegetables
    (17,20,21,27,28)
*  Indicates well-established risk factors with strong evidence for relationship with OC.
†  In an area of high incidence in northern China, having more than one relative with oesophageal cancer increased the RR for OC to 
1.9 (17). 
†† Many contradictory studies exist. The only study to date looking at HPV in Kenya has shown no association with the development of 
OC (18).
†††  Evidence to date for a specific correlation between the mycotoxin fumonisin (produced by the mold Fusarium moniliforme—a 
common contaminant of maize) and the development of OC is contradictory at best (19).
†††† H. pylori infection appears to be protective for AC (17,19), while a risk factor for OSCC. It has been suggested that the rising 
incidence of OC seen in western countries may in part be explained by the increasing treatment and eradication of H. pylori
infection (31)
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oesophagus (38). Light-induced fl uorescence 
endoscopy (LIFE) and narrow band imaging 
(NBI) are two additional endoscopic techniques 
for improving sensitivity in fi nding early 
lesions. NBI, or virtual chromoendoscopy, 
in particular, appears to be very promising 
in this regard without the use of additional 
reagents (39). Oesophageal capsule endoscopy 
also is being used for Barrett’s screening and 
surveillance programs. One clear disadvantage 
of this technique is the inability to obtain 
biopsy samples for histologic confi rmation (40). 
Optical coherence tomography (OCT) is also a 
technique with some promise in distinguishing 
neoplasia within Barrett’s mucosa (41). Use of 
these techniques in early diagnosis of OSCC 
has not achieved widespread success, but have 
shown promise in a number of studies in high-
risk populations (42,43).
Initial diagnostic evaluation tends to be 
either with barium swallow or upper endoscopy. 
The decision between these two modalities 
tends to be based upon regional availability 
of resources and referral patterns. Certainly, 
upper endoscopy is more reliable than contrast 
radiography, as small lesions can be missed 
on barium studies. Further, endoscopy allows 
for biopsy of suspicious lesions, permitting 
histologic confi rmation of disease. In areas 
where OC is endemic, the clinical presentation 
of weight loss and dysphagia is nearly 
pathognomonic for OC (4). This fi nding is 
virtually reproduced in the author’s institution, 
with the exception of cases of oesophageal 
candidiasis related to AIDS, which may cause 
severe dysphagia and weight loss as well. 
Additional diagnostic modalities with their 
appropriate uses in staging assessment are 
summarized in Table 3.
Staging of oesophageal 
cancer
The TNM staging system incorporated in the 
manual for Staging of Cancer of the American 
Joint Committee on Cancer (44) is the most 
widely used system for classifying OC. This 
scheme classifi es OC into stage 0 through stage 
IV based on tumour depth/penetration, nodal 
status, and presence of metastases. Superfi cial 
cancers are defi ned as tumours limited to the 
mucosa or submucosa (45). Mucosal lesions 
can be further subdivided into m1-m3 lesions. 
Tumours that are confi ned within the basement 
membrane are classifi ed as ml (described by 
some as “carcinoma-in-situ”). Lesions that invade 
into, but not through, the muscularis mucosa are 
considered m3. Lesions intermediate between 
these two would be considered m2. Submucosal 
lesions are similarly subdivided into sm1–sm3. 
The incidence of lymph node metastases in ml, 
Table 3: Diagnostic/staging modalities for oesophageal cancer
Diagnosis Use
    Upper GI endoscopy with biopsy Initial modalities of choice
Barium swallow
Primary tumour Assessment (T Stage)
    CT scan
    MRI
    Endoscopic Ultrasound
    Bronchoscopy
Tumour size and presence of invasion into surrounding tissue
Slightly superior to CT in detecting vascular invasion
Depth of invasion
Possible airway invasion for tumour above level of carina
Regional assessment (N Stage)
    CT scan
    Endoscopic ultrasound
Evaluating regional lymph nodes
Distant metastases (M Stage)
    CT scan
    PET scan
    Abdominal ultrasound
    Fine needle aspiration
Metastases detection especially liver and brain
Sensitive detection of distant metastases
Helpful for abdominal spread
Cervical or supra-clavicular lymph nodes
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m2 and m3 lesions has been reported at 0%, 
3.3%, and 12.2%, with sml, sm2, and sm3 lesions 
yielding a positive lymph node rate of 26.5%, 
35.8%, and 45.9%, respectively (46).
Management options
As described, historically patients have 
presented with OC only at late stages 
with advanced symptoms. In recent years, 
particularly in association with GORD and 
BO, a number of patients are being found with 
either pre-malignant dysplasia, or OC at a very 
early stage. For purposes of this discussion, 
management options will be discussed in 
the categories of superfi cial lesions and pre-
malignant dysplasia, invasive lesions with 
curative intent, and treatment with palliative 
intent.
Superfi cial lesions/Pre-malignant 
dysplasia
Multiple options exist for superfi cial 
malignant lesions of the oesophagus, including 
oesophagectomy, a variety of ablative therapies, 
and endoscopic mucosal resection (EMR). In 
most cases, ablative therapies are considered 
for pre-malignant dysplasia, but not for 
superfi cial carcinomas. Oesophagectomy has 
been advocated for high grade dysplasia (HGD) 
and early cancers, while EMR has been used for 
all grades of dysplasia and early carcinomas. 
Ablative therapies and EMR are generally 
considered for one of two reasons. First, given 
the relatively low risk of lymphatic spread with 
very early lesions, and the ability to completely 
remove or ablate the lesion endoscopically, the 
inherent morbidity and mortality associated 
with oesophagectomy may be avoided without 
compromising appropriate oncologic treatment 
principles and survival advantage. Second, 
individual patients often have associated co-
morbidity making treatment without the risk of 
oesophagectomy very attractive.
Currently, a number of different ablative 
therapies are available (47). The goal in all of 
these therapies is to achieve tissue destruction 
to various levels of the mucosa or submucosa. 
After ablative therapy, patients are generally 
maintained on effective acid suppression 
therapy while allowing normal healing of the 
damaged tissue. Descriptions of a number of 
ablative techniques as well as their relative 
advantages and disadvantages are summarized 
in Table 4.
Endoscopic Mucosal Resection (EMR) is a 
technique whereby portions of the oesophageal 
mucosa and submucosa can be removed via 
the endoscope. Therefore, unlike the ablative 
techniques, tissue is retrieved during EMR for 
histologic examination. Several different specifi c 
techniques exist. However, all of them have 
the general principle of submucosal injection 
of saline (with or without epinephrine or dye) 
to delineate a submucosal plane and facilitate 
resection. The involved mucosa, and varying 
degrees of submucosa, are then resected using 
electrosurgical techniques.
Newer variations of EMR, such as 
endoscopic submucosal dissection, have 
allowed the resection of progressively larger 
and deeper lesions. These techniques have been 
frequently pioneered and further developed 
by Japanese endoscopists (53). Although EMR 
was initially considered only in cases of pre-
malignant lesions, or very superfi cial malignant 
lesions (i.e. ml lesions), the indications are 
becoming broader, and some authors are now 
advocating use of EMR for m3 and even sm1 
lesions, provided they are less than 25 mm in 
diameter and have no evidence of lymphatic 
invasion (54). In appropriately selected patients, 
EMR can achieve complete local remission in 
more than 90% of cases of HGD and superfi cial 
cancers, although recurrence of malignancy 
may occur in approximately 25% of cases 
(55). Bleeding complications with EMR are 
more common (17%), but few require specifi c 
intervention, and stricture formation occurs in 
6%-23% of cases (55).
Invasive lesions with curative 
intent
While radiation therapy alone, or in combination 
with chemotherapy has been used in some cases 
with a small number of long term survivors, in 
general, surgical resection is the mainstay of 
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therapy in cases where pre-operative evaluation 
indicates that cure is possible and the patient is 
fi t for surgery. The areas of controversy include 
the type and “radicality” of resection, the extent 
of surgical lymphadenectomy, and the addition 
of adjuvant therapy.
Type of Surgical Resection
The three main types of surgical resection 
being performed today include the trans-
thoracic oesophagectomy (TTO), transhiatal 
oesophagectomy (THO) and more recently the 
minimally invasive oesophagectomy (MIO). 
The TTO procedure can be performed via 
either a right or left thoracotomy, although 
the right-sided thoracic approach is certainly 
more common and accepted. The classic Ivor 
Lewis TTO begins with a laparotomy for gastric 
mobilization, followed by right thoracotomy 
and tumour mobilization and resection. 
Gastrointestinal continuity is restored by an 
anastomosis between the gastric fundus and 
the proximal oesophagus in the apex of the 
right chest. The three-fi eld approach is a variant 
of the TTO and begins with a right thoracotomy 
for tumour and oesophageal mobilization. The 
chest is then closed and a laparotomy and left 
cervical incision is performed. The oesophagus 
is divided in the neck and the specimen is 
removed via the abdomen, with the anastomosis 
placed in the left neck. The THO, or so-called 
blunt oesophagectomy, involves a laparotomy 
and left cervical incision only. The thorax is 
never opened, and the tumour and oesophagus 
are mobilized and resected via blunt, transhiatal 
dissection. The gastro-oesophageal anastomosis 
is created in the left cervical position. The MIO 
has only recently emerged as an option and is 
going through signifi cant evolution. However, 
in general, this approach involves thoracoscopic 
mobilization of the tumour and oesophagus, 
Table 4: Ablative techniques for Barrett’s oesophagus and dysplasia
Technique Description Advantages Disadvantages
PDT (48) Systemic administration of a chemical 
photosensitizer. Light is applied 
endoscopically to the area generating 
oxygen free radicals and toxic species 
leading to tissue destruction
High effectiveness in 54-
87%
Complications of chest pain, 
cutaneous toxicity (30%), fever 
(33%), pleural effusions (33-75%), 
stricture (58%) 
High Cost
MPEC (49) Utilizes thermal energy with an 
electrical circuit between two or 
more electrodes on a probe tip that is 
passed through an endoscope
Success rates of 75%
Low cost
Less serious complications
Low success with long lesions 
Complications of dysphagia, 





A variety of different lasers. Utilizes 
the heat of laser directed at the lesion 
to destroy tissue
Less serious complications High cost
Subsquamous metaplasia (90%)
APC (50) Involves passing a monopolar electric 
current through ionized argon gas 
delivered via an endoscopic probe
Less depth of injury
Effective resolution of BO
(38-98.6%)
Serious complications including 
stricture, bleeding, perforation, 
and death occur in up to 24% 
Subsquamous metaplasia (30%)
RFA (51) Balloon-based bipolar electrode 
allows for circumferential destruction 









Involves the delivery of liquid nitrogen 
via a low pressure spray to cause 
tissue destruction through induced 
apoptosis and cryonecrosis




PDT =  Photodynamic Therapy, HGD = High Grade Dysplasia, MPEC = Multipolar Electrocoagulation, APC = Argon 
Plasma Coagulation, RFA = Radiofrequency Ablation
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followed by laparoscopic gastric mobilisation 
and transhiatal oesophagectomy, with a 
left neck incision and cervical anastomosis.
In general, oesophagectomy is a relatively 
morbid operation with high rates of complications 
and mortality, compared with other surgical 
procedures. The most common complications 
include pulmonary and cardiac complications, 
anastomotic leak and stricture formation. The 
rates of these complications vary signifi cantly 
between series, but overall complication rates 
are approximately 50%, and are summarised in 
Table 5. In general, most series show a higher 
rate of anastomotic leak for cervical anastomoses 
compared with intra-thoracic anastomoses. 
However, this fact must be considered in light 
of the fact that the mortality for an intra-thoracic 
leak is much higher than that for a leak in the 
cervical position. It is largely for this reason 
that this author’s personal practice is to place 
all oesophagogastric anastomoses in the neck.










Mortality related to oesophagectomy has 
been decreasing in recent years, but remains 
signifi cant, with most series reporting mortality 
rates of 5%-10% for patients resected for cure 
(57). Most advanced, high-volume surgical 
centres are now aiming for surgical mortality 
to be less than 5%. However, it is interesting 
to note that in the USA, a recent review of the 
Medicare database revealed a mortality rate 
that ranged from 8% in high-volume centers to 
23% in institutions in which the procedure was 
not commonly performed (58).
Signifi cant controversy exists in the surgical 
literature regarding the best surgical approach 
to OC. On the one hand is the “radical” 
philosophy advocating radical, en-bloc 
resection of OC, to include the primary tumour 
and the pericardium, thoracic duct, azygous 
vein, intercostal vessels, bilateral pleurae 
overlying the tumour, and a cuff of crura if the 
tumour is abutting. The associated two-fi eld 
lymphadenectomy involves en-bloc resection of 
all nodal groups between the tracheal bifurcation 
superiorly and the celiac axis inferiorly (59). 
This approach was fi rst proposed by Logan 
in 1963 (60), and further expanded upon by 
Skinner and colleagues in the early 1980’s (61). 
On the other hand is the view that OC tends 
largely to be a systemic disease at the time 
of diagnosis, and thus surgical intervention 
should be considered primarily palliative. This 
view is championed by Orringer and other 
advocates of the transhiatal oesophagectomy 
(62). A considerable body of evidence exists 
in the literature to support either view. A 
relatively recent meta-analysis of a decade of 
studies comparing TTO with THO showed no 
difference in 5-year survival between the two 
approaches, but signifi cantly higher morbidity 
and mortality with the TTO approach. One year 
later, the same authors published one of the few 
prospective, randomized studies comparing 
the two approaches, which included “radical” 
lymphadenectomy. This study showed no 
difference in mortality between TTO and 
THO, a statistically higher rate of morbidity 
with TTO, and a non-signifi cant trend toward 
improved survival in the TTO group (64). It is 
likely that this debate will continue indefi nitely 
and that surgical technique will continue to 
be largely infl uenced by regional training and 
practice patterns. It is this author’s opinion that 
the choice of the operation should be tailored to 
the individual patient characteristics, such that 
TTO should clearly be considered for upper and 
mid thoracic lesions, while THO is an option for 
distal lesions.
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Extent of Surgical 
Lymphadenectomy
The question of the appropriate extent 
of lymphadenectomy associated with 
oesophagectomy is related to, but separate from 
the question of surgical approach. While there 
are signifi cant variations in defi nitions in today’s 
literature, it is generally accepted that a “two-
fi eld” lymph node dissection involves resection 
of the nodes and peri-oesophageal tissue below 
the level of the carina and the lymph node 
stations around the celiac trunk. When superior 
mediastinal lymph node dissection is added 
to this, it is frequently referred to “extended 
or total two-fi eld lymphadenectomy” (65). 
However, in Japanese literature, the addition 
of the superior mediastinal lymphadenectomy 
is often assumed. The term “three-fi eld 
lymphadenectomy” implies the addition of 
bilateral cervical lymph node dissection. The 
rationale for this radical lymphadenectomy 
is based on the fi nding that up to one third of 
patients undergoing curative resection for OC 
will have occult cervical lymph node metastases 
(59). In relation to the primary tumour location, 
cervical node involvement is found in 60%, 
20%, and 12.5% of upper, mid, and lower 
third tumours respectively (64). Once again, 
one can fi nd ample evidence to support the 
view that a more extended lymphadenectomy 
improves survival (66), or that a more extended 
lymphadenectomy does not improve survival 
(62). One common argument against the 
evidence supporting improved survival in 
more extended lymphadenectomies is the 
observation of stage migration. This refers to 
the situation in which the additional dissection 
upstages a patient. Therefore, a patient who 
would have been staged at a lower stage (e.g. 
stage I or II) is upstaged to stage IV based on 
the cervical lymphadenectomy. By removing 
this patient from the early stage patients, it then 
improves observed survival in this group of 
patients. It would also appear that the additional 
dissection of the three-fi eld lymphadenectomy 
does increase morbidity (67), although there are 
signifi cant variations between surgical centers. 
Currently, three fi eld lymphadenectomy is 
commonly performed in Japan, while few 
western centers perform this procedure with 
regularity. Again, it appears that this debate 
will continue and that practice patterns will 
largely be determined by training patterns and 
personal choice.
Adjuvant Therapy
A great deal of interest has been expressed 
in recent years regarding adjuvant therapy 
in the treatment of OC. Focus has shifted 
to pre-operative (so-called neoadjuvant) 
chemotherapy and combined chemoradiation 
therapy since radiotherapy alone has not 
proved to be effective (68). Post-operative 
chemoradiation therapy has also not shown 
promise (69). A number of randomized studies 
have compared neoadjuvant chemotherapy 
and surgery to surgery alone (70,71). Of these 
studies, only the MRC trial (the largest of the 
trials) showed a statistically signifi cant survival 
advantage with hazard ratio of 0.79 and 95% 
confi dence interval of 0.67-0.93 (71). In a similar 
fashion, numerous randomized studies have 
compared neoadjuvant chemoradiation therapy 
and surgery and with surgery alone (70,72). Of 
these studies, only two have shown signifi cant 
survival advantages with a hazard ratios of 
0.58 and 95% CI 0.38-0.88 (72). In many of these 
studies, morbidity (up to 80%) and mortality 
(2%-8%) associated with adjuvant treatment 
has been signifi cant (73). A number of different 
meta-analyses have been performed attempting 
to combine the results of these relatively 
small randomized series (74,75). In general, 
these meta-analyses have failed to show any 
signifi cant improvement in survival with 
adjuvant treatment. However, one of the most 
recent studies has demonstrated signifi cant 
improvement in survival for both neoadjuvant 
chemotherapy and chemoradiation therapy. 
This meta-analysis included several non-
published studies which had not been included 
in previous analyses (76,77). One of these studies 
(77) showed a marked improvement in survival 
favoring neoadjuvant chemoradiation therapy 
and surgery over surgery alone. This meta-
analysis reported a hazard ratio for all-cause 
mortality with neoadjuvant chemoradiation 
therapy and surgery versus surgery alone of 
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0.81 (95% CI 0.70-0.93; p = 0.002), corresponding 
to a 13% absolute difference in survival at two 
years. This result differed slightly for OSCC 
with hazard ratio of 0.84 (95% CI 0.71-0.99; 
p = 0.04), than for AC with a hazard ratio of 
0.75 (95% CI 0.59-0.95; p = 0.02). The hazard 
ratio for neoadjuvant chemotherapy was 0.90 
(95% CI 0.81-1.00; p = 0.05), which indicates a 
two-year absolute survival benefi t of 7%. This 
benefi t was signifi cant for AC with a hazard 
ratio of 0.78 (95% CI 0.64-0.95; p = 0.014), was 
not statistically signifi cant for OSCC (75). This 
result has led some to consider neoadjuvant 
treatment as the standard of care for OC (78). 
While it seems clear that patients who achieve 
a complete pathologic response to neoadjuvant 
therapy appear to have improved survival (79)
and that neoadjuvant therapy may downstage 
patients and improve rates of complete surgical 
resection (80), it is not entirely clear what 
group of patients will ultimately benefi t from 
neoadjuvant therapy. A recent study combined 
a meta-analysis of survival benefi t with decision 
analysis evaluating relative risk for mortality 
and quality of life. This study demonstrated 
a very small increase in quality adjusted life 
years for neoadjuvant chemoradiation therapy 
and surgery compared with surgery alone, 
and concluded that surgery alone may be the 
preferred treatment in advanced OC (74). On a 
global basis, it appears that neoadjuvant therapy 
will likely become standard of care in resource 
rich areas (such as westernized countries 
where AC is more common), while surgical 
resection alone will remain the cornerstone of 
treatment for much of the world where OSCC 
predominates.
Treatment with palliative intent
Recognizing that less than one third of patients 
with OC are candidates for operative treatment 
with curative intent, it is obvious that palliation 
will be the goal in the majority of patients with 
OC (81). Palliation is defi ned as the easing 
of symptoms without curing the underlying 
disease. Since the majority of the serious 
symptoms related to incurable OC are related 
to oesophageal obstruction (i.e. dysphagia and 
weight loss), the goals of palliation are generally 
directed toward overcoming oesophageal 
obstruction and improving dysphagia. Chest 
and abdominal pain are generally managed with 
narcotic and non-narcotic pain medications, 
while bleeding is particularly diffi cult to palliate 
without resection.
Virtually all of the ablative techniques 
previously described have been used for 
palliation of advanced OC (82-86). Additionally, 
chemotherapy, radiation therapy, brachytherapy, 
direct ethanol injection, endoscopic intubation 
or stenting, and palliative surgery have all been 
utilized in the treatment of OC not amenable to 
resection (87-92). The simple fact that so many 
options exist would certainly seem to imply 
that there is no clear consensus on the most 
effective palliative technique. However, several 
observations should be made. When one talks 
of palliative surgical treatment of oesophageal 
cancer, the most common situation is that 
of discovering that a tumour is unresectable 
or discovering the presence of metastases at 
the time of attempted surgical resection. The 
literature is in fact nearly absent of studies 
looking specifi cally at surgical palliation which 
was planned pre-operatively, with only one clear 
study in this area. This is due to the inherent 
diffi culty in surgically treating OC with anything 
less than resection. Partial resection or debulking 
procedures are nearly always fraught with 
complications and mortality. It is this author’s 
opinion that during surgical exploration for 
intended resection, if the surgeon does not feel 
reasonably sure that at minimum an R1 resection 
can be carried out (in which all gross disease is 
removed)—and preferably an RO resection 
(in which microscopic margins are negative), 
then no resection should be performed, and an 
alternate form of palliation should be pursued. 
Surgical bypass is diffi cult to perform due to the 
anatomic position of the oesophagus, and carries 
a very high rate of morbidity and mortality.
While chemotherapy alone has not 
been shown generally to provide signifi cant 
palliation, chemoradiation therapy, or radiation 
therapy alone seems to provide temporary 
improvement in swallowing in appropriately 
selected patients. Radiotherapy has been 
utilized particularly in proximal oesophageal 
lesions, where other palliative treatments are 
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more diffi cult. All of the ablative techniques 
used for palliation have met with some success. 
However, common to all of these techniques.
is the need for re intervention, with dysphagia 
often recurring as soon as one month after 
treatment (94). In patients with non-curable OC, 
survival is measured in weeks and months, and 
so providing palliation with as few treatment 
sessions as possible is certainly preferable.
Endoscopic intubation or stenting has 
become more common in recent years, and is 
now the most common technique utilized for 
palliative treatment of advanced OC (91). In 
earlier years, stenting was performed with a 
variety of plastic, metal, or wooden prostheses. 
A nice review of the history of stenting is 
provided by Mitton and Ackroyd (91).. Common 
to all of these prostheses was the diffi culty in 
insertion often requiring general anesthesia 
and laparotomy. Additionally, these fairly 
rigid, smooth prostheses had a very signifi cant 
rate of migration (95). The introduction of 
self-expanding metal stents (SEMS) in 1983 
heralded the beginning of a new era in the use 
of stents (96). Since that time, the use of SEMS 
has virtually replaced rigid endoprostheses in 
much of the world. The procedure of inserting 
SEMS is generally performed with conscious 
sedation. Although fl uoroscopy may be helpful 
in placement, it is certainly not required (97). 
Currently, SEMS with a plastic coating are 
most commonly used to reduce the incidence 
of tumour ingrowth through the interstices of 
the stent. Stent placement can be performed as 
an outpatient procedure, and combined with 
dilation, provides immediate improvement in 
dysphagia. Early or immediate complications 
are generally related to dilation or misplacement 
and include perforation and airway compromise. 
Whereas oesophageal perforation is generally 
considered a surgical emergency, perforation 
of an unresectable malignancy can usually be 
treated effectively with placement of a coated 
SEMS (98). Later complications of SEMS include 
chest pain, stent migration, stent occlusion, and 
bleeding. Morbidity and mortality is clearly 
lower with SEMS than with rigid prostheses 
(99). While some have reported complications 
as high as 16%-45% and mortality rates as 
high as 9%, (99). Others have reported 5% late 
complications and 0% mortality with very good 
reduction in dysphagia until death (100).
Outcome/survival
On a global basis, overall 5-year survival of OC 
is signifi cantly less than 10% (29,101). In the 
USA, the American Cancer Society estimated 
that there would be 11,260 new cases of OC in 
men, and 3,290 cases in women. In the same 
year they estimated that 10,730 men and 3,040 
women would die of the disease, indicating very 
high case fatality (7). In the USA, 5-year survival 
estimates for OSCC has improved from 4.6% in 
1974-1979 to 12.3% in 1992-1997, while AC has 
seen an improvement from 5.3% to 13.7% for the 
same time period (102). In patients undergoing 
potentially curative resection, overall 5-year 
disease-free, all-stage survival is approximately 
30% with median survival of 21 months (64,103). 
This is, of course, highly dependent upon the 
stage of the disease at the time of diagnosis and 
treatment, and is summarised in Table 6.
Table 6: Survival following oesophagectomy for oesophageal cancer
Stage 5-year survival (%) Median Survival
0 68-100 NR*
I 42-78 44-78 months
II 26-72 23-59 months
III 15-39 14-53 months
IV 0-27 7-20 months
*NR: Not Reported
Source: 59, 103,106
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The most important prognostic factors 
for patients undergoing surgical resection for 
OC appears to be the ability to carry out an 
RO resection, and the presence (and absolute 
number) or absence of involved lymph nodes. 
There are, however, a number of other factors 
which have prognostic signifi cance, and these 
are summarised in Table 7.
Table 7: Prognostic factors following oesophagectomy 
for oesophageal cancer
Weight loss before operation
Duration of symptoms
Tumor location (proximal tumors indicate worse 
prognosis)
Radicality of resection (i.e. RO vs. R1 vs. R2)
Pathologic Stage






Oesophageal cancer in 
Kenya
Relatively few published reports exist 
regarding the situation of OC in Kenya. The 
earliest published report is from a colonial 
offi cer in 1935 who reported several cases of 
OC (108). Nevill then reported 79 cases of OC 
from what is now Kenyatta National Hospital 
in Nairobi (109). Ahmed and Cook published 
several case-series from 1966 to 1971, with OC 
accounting for 25%-30% of all cancers (110,111). 
These reports indicated that in certain regions 
of central and west Kenya, OC ranked as the 
fi rst or second most common cancer. In 1978, 
Gatei and colleagues reported OC as the fi fth 
most common cancer nationwide, accounting 
for 5.4% of solid malignancies (112). This study 
reported an overall incidence for the country of 
0.67 per 100,000 per year. This would imply that 
Kenya is an area of extremely low incidence of 
OC. Further, they reported the incidence of OC 
among the Kalenjin tribes at 0.2 per 100,000 per 
year. Unfortunately, these rates were based solely 
on cases that were histologically confi rmed at 
the central pathology laboratory in Nairobi and 
reported to the Kenya Cancer Registry. Since 
most of the hospitals did not have the resources 
to perform histological studies, these numbers 
clearly grossly underestimated the actual 
incidence. White et al reported their experience 
with OC in southwestern Rift Valley Province 
from 1989 to 1998 (5). In our series, OC was the 
most common malignancy for both men and 
women, accounting for 19% of all malignancies. 
The male to female ratio was 1.4 to 1 with OSCC 
accounting for 90% of cases. The median age at 
diagnosis was 54 for men and 56 for women. 
There was a signifi cant proportion of patients 
presenting at a young age, with 11% of cases 
aged 30 years or less, with the youngest patient 
presenting at age 14. This is quite a striking 
fi nding which has not been reported in any other 
place world-wide. Even in areas of extremely 
high incidence of OC, such as Linxian, China, 
cancer cases in people aged 30 years or less are 
extremely rare, with a proportion of less than 
1% (113). In western countries, such as the USA, 
this proportion is even lower at 0.18% (10).
More recently, Wakhisi et al. described 
the experience with OC at Moi Teaching and 
Referral Hospital in Eldoret (4). They described 
OC as the most common cancer in men, and 
the third most common malignancy in women. 
In this series, OC accounted for 13.8% of all 
malignancies, with OSCC accounting for 90% of 
cases. The male to female ratio was 1.5 to 1. The 
mean age at diagnosis was 59 years, with 10% 
of cases less than 40 years old. The youngest 
patient in the series was 20 years old. This 
series attempted to describe an incidence rate 
of more than 30 per 100,000 per year for men, 
with approximately half of that for women. 
However, it is very unclear how this incidence 
was calculated. Recognizing the inherent 
diffi culty in establishing valid incidence rates 
(i.e. assuring that all cases are reported, and 
knowing the number of the total population at 
risk), it is probably wiser not to report incidence 
rates. Elsewhere in Kenya, the Nairobi Cancer 
Registry reported cancer cases registered 
during 2000-2002. They found that OC was the 
most common single site cancer among men at 
10% of all malignancies, while it was third most 
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common (behind breast and uterus/cervix) 
accounting for 4.4% of all malignancies (114).
It is clear that OC is one of the most 
common cancers in Kenya. Whether or not 
specifi c geographic sites of very high incidence 
within the country exist is not clear at this point. 
What is clear to anyone who sees OC patients in 
Kenya with regularity is that the vast majority 
of patients are presenting at a very late stage. 
For most patients, surgical resection for cure 
is not an option due to either very late stage 
disease, very poor overall condition of the 
patient, or both. Very little has been done to 
identify patients at early stages of the disease, 
although at least one study has been reported 
looking at the feasibility of a screening program 
for OC in Kenya (115). At Tenwek Hospital, 
patients with OC undergo upper GI endoscopy, 
chest radiograph, abdominal ultrasound and 
HIV testing. Patients with upper oesophageal 
lesions also undergo bronchoscopy. The 
exclusion criteria for surgical resection are 
summarized in Table 8. Those found to have 
no contraindications for surgical resection 
(generally approximately 10% of all OC patients 
seen) are offered surgery with curative intent. 
The remaining 90% of patients are usually 
offered stenting with self-expanding metal 
stents. In general, it is diffi cult to arrange either 
adjuvant or primary chemotherapy or radiation 
therapy for the majority of OC patients in 
Kenya. Therefore, either surgical resection 
alone or stenting alone are the treatments most 
often available for patients with OC.
A great deal of work remains to be done 
regarding OC in Kenya. These projects include 
clarifying epidemiologic trends and patterns, 
examining potential risk factors and etiologies, 
further defi ning the role of screening programs 
and early intervention, clarifying the role of 
surgical and adjuvant treatment, and improving 
the availability of palliative care for the many 
cases of advanced OC which will surely 
continue to present to many health care workers 
throughout the country. There is a tendency to 
become somewhat fatalistic when dealing with 
this disease in our context. This has led some 
to question whether there is any hope at all for 
making progress regarding OC (12). However, 
with appropriate work and diligence, there 
is tremendous potential to make signifi cant 
contributions toward the understanding of this 
disease, and to provide preventative, curative, 
and palliative care to a very large number of 
people in need.
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